ZEISS MyoActive Launch: Dynamic Signal Theory and Efficacy Claims

Zeiss Vision Care has introduced Zeiss MyoActive, a spectacle lens solution designed to slow myopia progression in children. The lenses utilize Dynamic Signal Theory, combining myopic defocus with dynamic signal variation via patented M.O.V.E. (Micro Optical Variable Elements) technology. This nonrepetitive microstructure layout creates continuously changing retinal signals as the eye moves, aiming to reduce visual adaptation. Additionally, the back surface employs ZeissClearFocus design to minimize peripheral hyperopic defocus. Zeiss MyoActive is currently available in Canada and several European markets. The company states that the lenses are under research and review in other regions, including China and the United States, but have not yet received approval there.

ZEISS Vision Care announced MyoActive, a spectacle lens for children with myopia, on October 1 from its Aalen headquarters. The company claims it is its most effective myopia management lens to date, utilizing "Dynamic Signal Theory" and patented M.O.V.E. technology to prevent visual adaptation to the myopia control signal. In a randomized controlled trial conducted by the Shanghai Eye Disease Prevention and Treatment Center involving 56 children aged 7–13, ZEISS reported that MyoActive wearers showed 0.60D less myopia progression and 0.22mm less axial elongation compared to a single-vision control group over 12 months. Mean progression was -0.23D per year. The data are currently listed as "data on file" and have not been peer-reviewed. Australian availability, pricing, and regulatory status were not included in the announcement.

ZEISS Vision Care has launched ZEISS MyoActive, a new spectacle lens designed for myopia management in children. Announced on October 1, it is described as the first lens to apply the company's Dynamic Signal Theory. ZEISS claims that MyoActive delivers the highest average efficacy among myopia control spectacle lenses available. The product targets pediatric vision care needs through this specific technological approach.

ZEISS Vision Care announced the global launch of MyoActive on 1 October, introducing a spectacle lens designed to correct children’s vision and slow myopia progression. The company describes it as the first myopia management lens applying Dynamic Signal Theory, combining myopic defocus with variable signals via Micro Optical Variable Elements (M.O.V.E.) on the front surface and ClearFocus design on the back. ZEISS reports clinical results from an ongoing two-year trial in China showing that after 12 months, children wearing MyoActive had 0.60 dioptres less myopia progression and 0.22 millimetres less axial elongation compared to those wearing single-vision lenses. Mean progression in the MyoActive group was -0.23 D. ZEISS states 98% of children adapted within one week. MyoActive joins the ZEISS Myopia Management Collective.

The optical industry introduced new lens and technology products for the fall season. Signet Armorlite launched Kodak Precise Next Lenses, featuring near zone amplification to accelerate power progression. EssilorLuxottica released Crizal Natural Look coating to reduce reflections and highlighted Stellest lenses, the first FDA-approved eyeglass lenses designed to slow myopia progression in children ages 6 through 12. VSP Optics offered TechShield Sun UVR, an anti-reflective coating for sun lenses compatible with all materials. IOT introduced Neochromes ONE photochromic lenses, claiming up to 20 percent darker performance in high temperatures, and Neochromes Vibe for aesthetic customization. Hoya Vision Care unveiled Sensity 3, stating it is up to 4x more resistant to reaction fatigue than leading competitors. Schneider announced CCU Modulo Zero hybrid linking technology and Modulo Center ONE Pro, which delivers up to 40 percent higher throughput in a compact footprint.